

Topical Aloe Vera as an Adjunctive Therapy for Diabetic Foot Ulcers: A Systematic Review

Syafiq Maulana^{1*}

^{1*} Medical Profession Program, Faculty of Medicine and Health Sciences, UIN Maulana Malik Ibrahim Malang, Malang, East Java, Indonesia

ARTICLE INFO

Article history:

Received 13 January 2026

Accepted 11 April 2026

Published 20 April 2026

Keyword:

Aloe vera

Diabetic foot ulcer

Wound healing

Adjuvant therapy

**) corresponding author*

Syafiq Maulana

Email: syafiq.ma03@gmail.com

DOI: 10.47679/makein.2026308

ABSTRACT

Diabetic foot ulcers (DFUs) remain a persistent clinical challenge due to impaired healing and high infection risk. This systematic review evaluates the potential benefit of topical Aloe vera as an adjunct to standard DFU care. A structured search of PubMed, ScienceDirect, ProQuest, and Google Scholar was conducted up to December 30, 2025, following PRISMA 2020 guidelines. Eight clinical studies (six randomized controlled trials/RCTs and two quasi-experimental studies), involving 402 patients, were included. Outcomes assessed included BWAT/BJWAT scores, granulation, epithelialization, and ulcer size. Across studies, Aloe vera was associated with improvements in wound healing parameters, particularly in mild-to-moderate, non-ischemic ulcers during early healing phases. Risk of bias assessment showed generally low to moderate concerns among RCTs, while non-randomized studies presented serious to critical risk of bias. Using GRADE, the certainty of evidence was low for wound scores and ulcer size reduction, and very low for granulation and healing outcomes, mainly due to risk of bias, inconsistency, and imprecision. Overall, Aloe vera may provide some benefit as a low-cost adjunctive therapy; however, the current evidence remains limited and should be interpreted with caution. Further well-designed, adequately powered trials with standardized outcomes are needed.

This open access article is under the [CC-BY-SA](#) license.



INTRODUCTION

Patients with diabetes mellitus are highly vulnerable to a range of chronic complications, including nephropathy, retinopathy, and neuropathy. Among the most severe of these is diabetic foot ulcers (DFUs) (Wang et al., 2022). DFUs are defined as tissue damage extending to at least the dermal layer in individuals with diabetes, and they are estimated to affect 19–34% of patients over their lifetime (McDermott et al., 2023). Globally, around 18.6 million new DFU cases occur each year, placing a substantial burden on morbidity, quality of life, and healthcare systems (Armstrong et al., 2023). If not managed appropriately, DFUs can progress to severe infection, gangrene, lower-limb amputation, and even death (Ndosi et al., 2018). The five-year mortality rate in patients with DFUs is reported to be approximately 30%, rising sharply following major amputation, with significant associated healthcare costs (Chia et al., 2025). In resource-limited settings, restricted access to advanced wound care further worsens patient outcomes (Ahn & He, 2026). Accelerating wound healing is therefore a critical priority to reduce both the clinical and economic burden of DFUs.

From a pathophysiological perspective, DFUs represent a complex condition arising from the interplay of neuropathy, ischemia, infection, and metabolic dysfunction (Dawi et al., 2025). Peripheral neuropathy leads to loss of protective

sensation and increases the risk of repeated trauma, while peripheral arterial disease contributes to tissue hypoxia and impaired nutrient delivery (Parveen et al., 2025). Chronic hyperglycemia further drives persistent inflammation, oxidative stress, and endothelial dysfunction, all of which impair angiogenesis and immune responses (Dubský et al., 2026). In addition, dysfunction of fibroblasts and keratinocytes disrupts extracellular matrix formation and re-epithelialization, ultimately delaying wound healing (Hassan et al., 2026). Together, these factors create a hostile wound environment characterized by a high risk of infection and poor healing outcomes, even when appropriate treatment is provided (Armstrong et al., 2023).

Current DFU management relies on a comprehensive approach that includes debridement, infection control, off-loading, vascular optimization, glycemic control, and appropriate wound dressings (Everett & Mathioudakis, 2018). Despite this, healing is often prolonged and suboptimal, as standard therapies do not fully address chronic inflammation, impaired angiogenesis, oxidative stress, and high microbial burden in DFU wounds (R. Wang et al., 2025). Moreover, advanced wound care technologies, such as biomaterial-based therapies and specialized dressings, are frequently limited by cost and availability, particularly in low-resource settings (Pinem et al., 2025). This highlights the need for adjunctive therapies that can complement, rather than

replace, standard care. In this context, Aloe vera has gained attention as a topical agent used alongside conventional treatment to help improve the wound environment (Matei et al., 2025).

Aloe vera contains a range of bioactive compounds with anti-inflammatory, antioxidant, and antimicrobial properties. It has also been shown to promote fibroblast proliferation, collagen synthesis, and re-epithelialization, suggesting potential benefits in overcoming key barriers to DFU healing (Matei et al., 2025). Several clinical trials have reported that adding Aloe vera to standard wound care improves healing outcomes compared to standard care alone, including reductions in wound scores and faster tissue repair (Irani et al., 2024; Sandhiya et al., 2025). However, it is important to emphasize that Aloe vera should be considered an adjunctive therapy that supports healing, rather than a substitute for essential interventions such as debridement, off-loading, and infection control. Although there are indications that Aloe vera may be more affordable than some conventional agents in certain wound contexts, evidence regarding its cost-effectiveness remains limited and cannot yet be generalized to DFUs (Shahzad & Ahmed, 2013).

Despite its promising potential, the current body of evidence remains fragmented and heterogeneous. Some previous systematic reviews have evaluated Aloe vera across a broad range of wound types without specifically focusing on DFUs, limiting their clinical applicability to this population (Idrus et al., 2023; Hekmatpou et al., 2019). Conversely, systematic reviews focusing on DFUs often assess a wide range of herbal interventions without specifically examining the effectiveness of Aloe vera as a standalone therapy (Narzary et al., 2023). In addition, a systematic review protocol specifically targeting Aloe vera in DFUs has been published, but a comprehensive synthesis of results is not yet available (Jamiyanti et al., 2023). Variability in study design, intervention formulations, and reported outcomes further underscores the need for a more focused and rigorous evaluation of the evidence.

Based on these considerations, this study aims to systematically evaluate the effectiveness of topical Aloe vera as an adjunctive therapy in the healing of diabetic foot ulcers. The research question is formulated as follows: in patients with DFUs (Population), does the use of topical Aloe vera (Intervention), compared with standard care or other conventional interventions (Comparator), improve wound healing outcomes such as ulcer size reduction and wound closure (Outcomes)? By focusing on a clearly defined population, intervention, and clinically relevant outcomes, this review aims to provide a more targeted and practical synthesis of evidence for clinical application.

METHODS

Study Design

This systematic review was conducted using methodological guidance from the Cochrane Handbook for Systematic Reviews of Interventions and was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement (Higgins et al., 2024; Page et al., 2021). PRISMA 2020 was used to promote transparent and complete reporting of the review process, whereas the Cochrane Handbook informed the methodological procedures for defining eligibility criteria,

identifying and selecting studies, extracting data, assessing risk of bias, and synthesizing the evidence.

An a priori internal protocol was developed before study selection. The protocol specified the research question, eligibility criteria, literature search strategy, study-selection procedures, data-extraction variables, risk-of-bias assessment, and planned approach to evidence synthesis. Predefining these methodological components is recommended in systematic reviews to improve consistency in study selection and analysis and to reduce the influence of post hoc decisions on the review process (Higgins et al., 2024). The protocol was not prospectively registered in a public registry such as PROSPERO; therefore, this limitation was considered when evaluating the transparency and reproducibility of the review process.

Search Strategy

A comprehensive literature search was conducted across four electronic information sources: PubMed, ScienceDirect, ProQuest, and Google Scholar. The final search was performed on December 30, 2025. The search strategy was developed using a combination of controlled vocabulary, where available, and free-text terms, consistent with recommendations for systematic-review searching that emphasize combining subject headings with relevant text words to maximize search sensitivity (Lefebvre et al., 2025). Reporting of the search process was also informed by the PRISMA-S extension, which emphasizes transparent documentation of information sources, search terms, search dates, and source-specific search strategies to improve reproducibility (Rethlefsen et al., 2021).

Search concepts represented two principal domains: the intervention (Aloe vera) and the clinical condition (diabetic foot ulcers [DFUs]). Terms related to Aloe vera included "Aloe," "Aloe vera," "Aloe barbadensis," "Aloe gel," and "Aloe extract," whereas DFU-related terms included "diabetic foot ulcer," "diabetic foot," "diabetic wound," "foot ulcer," and "diabetic feet." Within each concept, synonymous or related terms were combined using the Boolean operator "OR," whereas the intervention and condition concepts were combined using "AND." This approach is consistent with recommended systematic-search methods in which alternative terms within a concept are combined broadly to improve sensitivity, while distinct concepts are combined to increase relevance (Lefebvre et al., 2025).

The search syntax was adapted to the indexing structure and search interface of each information source. Source-specific filters or limits, where available, were applied before exporting records to restrict eligibility to original interventional studies published between 2015 and 2025, in accordance with the predefined eligibility criteria. In addition to electronic searching, the reference lists of included studies were manually screened to identify potentially relevant studies that may not have been captured by the primary searches, as supplementary reference-list searching is recommended to improve the comprehensiveness of systematic-review searches (Lefebvre et al., 2025). The complete search strategy and number of records retrieved from each source are presented in Table 1.

Eligibility Criteria

Study eligibility was defined a priori using an operationalized PICOS framework encompassing Population, Intervention, Comparator, Outcomes, and Study design. The

use of an explicitly formulated eligibility framework is recommended to ensure that study inclusion is aligned with the review question and that eligibility decisions are applied consistently throughout the review process (Higgins et al., 2024).

The eligibility criteria were as follows: (1) Population: human patients with a clinical diagnosis of DFU, without restrictions on age, sex, ulcer size, ischemic status, or ulcer severity; (2) Intervention: topical Aloe vera, administered either as a single-agent formulation or as part of a combination formulation and used as an adjunct to wound care; (3) Comparator: standard or conventional wound care, including debridement, saline irrigation, conventional dressings, topical placebo, or other relevant comparator interventions; (4) Outcomes: the primary outcomes were objective measures of wound healing, particularly changes in

wound-assessment scores and ulcer-size reduction. Secondary outcomes included time to wound closure, granulation tissue formation, epithelialization, complete healing, and other clinically relevant wound-healing parameters; and (5) Study design: eligible studies were original interventional studies published between 2015 and 2025.

Non-human studies and publications that did not provide original clinical intervention data were excluded. These included narrative reviews, systematic reviews, meta-analyses, conference abstracts, commentaries, letters to the editor, case reports, and clinical guidelines. Studies were also excluded when the population, intervention, or outcomes did not correspond to the predefined review question or when sufficient clinical wound-healing outcome data were unavailable.

Table 1. Search strategies and records identified across information sources

Information source	Search strategy	Limits applied	Records retrieved
PubMed	("Aloe"[Mesh] OR "Aloe vera"[Title/Abstract] OR "Aloe barbadensis"[Title/Abstract] OR "aloe gel"[Title/Abstract] OR "aloe extract"[Title/Abstract] OR "aloe cream"[Title/Abstract]) AND ("Diabetic Foot"[Mesh] OR "diabetic foot ulcer"[Title/Abstract] OR "diabetic foot ulcers"[Title/Abstract] OR "diabetic foot"[Title/Abstract] OR "diabetic wound"[Title/Abstract] OR "diabetic wounds"[Title/Abstract] OR "foot ulcer"[Title/Abstract] OR "foot ulcers"[Title/Abstract])	Publication years: 2015–2025	68
ScienceDirect	("Aloe vera" OR "Aloe barbadensis" OR "aloe gel" OR "aloe extract" OR "aloe cream") AND ("diabetic foot ulcer" OR "diabetic foot ulcers" OR "diabetic foot" OR "diabetic wound" OR "diabetic wounds" OR "foot ulcer" OR "foot ulcers")	Publication years: 2015–2025; research articles	1,197
ProQuest	("Aloe vera" OR "Aloe barbadensis" OR "aloe gel" OR "aloe extract" OR "aloe cream") AND ("diabetic foot ulcer*" OR "diabetic foot" OR "diabetic wound*" OR "foot ulcer*")	Publication years: 2015–2025; scholarly journals/articles	1,415
Google Scholar	("Aloe vera" OR "Aloe barbadensis" OR "aloe gel" OR "aloe extract" OR "aloe cream") ("diabetic foot ulcer" OR "diabetic foot" OR "diabetic wound" OR "foot ulcer")	Custom year range: 2015–2025	796

Study Selection

All records identified through the literature search were exported and managed using Rayyan, a web-based platform developed to facilitate the screening and organization of records in systematic reviews (Ouzzani et al., 2016). Duplicate records were removed before eligibility screening.

Study selection was performed in two sequential stages. First, titles and abstracts were screened against the predefined eligibility criteria. Records considered potentially relevant at this stage were then subjected to full-text assessment. Studies that met all predefined inclusion criteria were retained for qualitative synthesis, whereas studies that failed to satisfy the criteria were excluded. Reasons for exclusion at the full-text stage were documented to ensure transparency in the selection process.

The identification, screening, eligibility assessment, and final inclusion of studies were summarized using the PRISMA 2020 flow diagram, which provides a standardized framework for documenting the number of records identified, removed before screening, screened, assessed for eligibility, excluded, and ultimately included in a systematic review (Page et al., 2021).

Data Extraction

Data were extracted using a standardized Microsoft Excel data-extraction form developed according to the predefined

review objectives. The use of a structured data-collection form is recommended in systematic reviews to promote consistent, transparent, and sufficiently detailed extraction of information on study methods, participants, interventions, outcomes, and results (Li et al., 2024).

Extracted data were organized into three principal domains: study characteristics, intervention characteristics, and study outcomes. Study characteristics included author, publication year, study design, sample size, participant age, DFU severity, baseline ulcer size, infection status, and glycemic status. Intervention characteristics included Aloe vera formulation, intervention type, relevant co-interventions, application method, frequency of administration, treatment duration, and comparator treatment.

Outcome data included changes in validated wound-assessment scores, ulcer-size reduction, and time to wound closure, as well as secondary outcomes such as granulation tissue formation, epithelialization, tissue characteristics, complete healing, and adverse events. Comparative findings between intervention and control groups, including the direction and statistical significance of effects where reported, were also extracted. Information that was unavailable in the original reports was coded as "not reported" (NR) rather than inferred. Extracted information was cross-checked against the source articles and the predefined extraction tables to maintain consistency and accuracy.

Quality Assessment

Risk of bias in the included studies was evaluated using design-specific assessment tools. Randomized controlled trials (RCTs) were assessed using the revised Cochrane Risk of Bias tool (RoB 2), which evaluates potential bias in specific study results across five domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome, and bias in selection of the reported result (Sterne et al., 2019). Domain-level and overall RoB 2 judgments were classified as low risk of bias, some concerns, or high risk of bias, in accordance with the recommended RoB 2 framework.

Non-randomized intervention studies were assessed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) framework. ROBINS-I evaluates seven domains covering bias due to confounding, selection of participants, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of the reported result (Sterne et al., 2016). Judgments for ROBINS-I were classified as low, moderate, serious, or critical risk of bias, with no information used when insufficient information was available for a judgment. Risk-of-bias assessments were taken into account when interpreting the direction, magnitude, and reliability of the observed intervention effects.

Beyond study-level risk of bias, the certainty of the overall body of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. GRADE provides an explicit framework for evaluating confidence in a body of evidence for individual outcomes and classifies certainty as high, moderate, low, or very low (Guyatt et al., 2008). Certainty was evaluated across five principal domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Downgrading decisions were based on the extent to which concerns within these domains reduced confidence that the observed effects represented the true intervention effect. The resulting GRADE judgments were incorporated into the interpretation of the findings to distinguish between potentially favorable treatment effects and the degree of confidence that could be placed in those effects.

Data Synthesis

A narrative synthesis was conducted due to heterogeneity in study designs, variations in Aloe vera formulations, and differences in reported outcomes, which precluded meta-analysis. The synthesis was structured using two complementary approaches: by outcome domain and by intervention type. Within each category, findings were analyzed to identify patterns in the direction and consistency of effects across studies, particularly for key wound healing parameters such as wound score reduction, ulcer size change, and time to wound closure. Differences in comparator type, wound severity, and co-interventions were also considered to contextualize variability in results. This approach enabled a more nuanced interpretation of trends, including areas of consistent benefit, mixed findings, and uncertainty, while taking into account methodological quality and certainty of evidence.

RESULTS OF STUDY

Results of the Literature Search

The systematic search identified 3,476 records from PubMed (n = 68), Google Scholar (n = 796), ScienceDirect (n = 1,197), and ProQuest (n = 1,415). Prior to screening, 463 duplicate records and 1,561 records flagged as ineligible by database filters (including publication year, study design, and article type restricted to academic journal articles) were removed, leaving 1,452 records for title and abstract screening. Of these, 1,406 records were excluded, and 46 articles were sought for full-text retrieval. Twelve reports could not be retrieved, resulting in 34 full-text articles assessed for eligibility. A total of 26 studies were excluded due to inappropriate intervention (n = 7), wrong patient population (n = 10; including non-DFU populations [n = 6] and non-human studies [n = 4]), or insufficient outcome data (n = 9). Finally, eight studies met the inclusion criteria and were included in the qualitative synthesis (Figure 1).

Characteristics of Included Studies

Eight clinical studies involving a total of 402 patients with DFUs were included, with sample sizes ranging from 17 to 66. The majority were RCTs, including several double-blind designs, while two employed quasi-experimental approaches. Participants were predominantly middle-aged to older adults, although one study included a broader age range (18–80 years). Ulcer severity varied substantially, from superficial grade 1 lesions to Wagner grade II–III ulcers and moderate-to-severe wounds requiring debridement. Key clinical variables were inconsistently reported across studies; infection status ranged from non-infected to moderately infected wounds, while glycemic control varied from well-controlled HbA1c levels (<6–7%) to hyperglycemia or was not reported. Ulcer size was also variably described, reflecting considerable heterogeneity in baseline wound characteristics (Table 2).

Characteristics and Types of Interventions

All included studies evaluated Aloe vera as an adjunct to standard wound care rather than as monotherapy. Interventions were broadly categorized into Aloe-only formulations (gel or dressing) and combination therapies (e.g., Aloe with honey or *Plantago major*). Most studies used topical Aloe gel applied once daily, although some applied it twice daily or every two days. Application methods varied from simple topical use to post-debridement protocols. Co-interventions were consistently present, including saline irrigation, dressings, debridement, antibiotics, and off-loading. Treatment duration ranged from 8 days to 8 weeks. Control groups received standard care, saline dressings, or placebo. Overall, variability in formulations, protocols, and co-interventions reflects the complexity of isolating Aloe vera's specific effect.

Main Outcomes

Primary Outcome

For primary outcomes, most studies assessed objective wound healing using validated scoring systems (BWAT/BJWAT) and ulcer size reduction. Overall, Aloe vera was associated with greater improvements in wound scores in several studies, including Sandhiya et al. (2025). (42–19 vs 43–25; p=0.0029), Daphne & Prince, (2019) (35–21 vs 33;

$p < 0.05$), and Malini et al. (2022) (45.6–32.3 vs 42.9–39.7; $p = 0.001$ vs 0.013). Najafian et al. (2019) also reported significant reductions in total ulcer score and surface area ($p < 0.001$; $p = 0.039$). However, Irani et al. (2024) found comparable improvements between groups ($p = 0.352$). For

size-based outcomes, Muslim et al. (2025) demonstrated greater ulcer reduction with Aloe (2.5 vs 1.2 cm²; $p < 0.01$), while Bahar et al. (2015) reported higher healing rates (95.5% vs 78.6%) without statistical significance.




Figure 1. PRISMA flow diagram for identification of relevant studies.

Table 2. Baseline Characteristics of Included Studies

Study	Design	N	Age (years)	DFU Severity	Ulcer Size	Infection Status	Glycemic Status
Aqsa et al., 2019	RCT	60	46.3 vs 47.4	Wagner I–II	NR	Infected	HbA1c <6
Irani et al., 2024	Double-blind RCT	66	57.7 ± 11.6 vs 56.2 ± 9.5	Grade 1 (superficial)	<10 cm ²	Non-infected	HbA1c <7
Muslim et al., 2025	RCT (3-arm pilot)	60	18–80	Wagner II–III	NR	NR	NR
Sandhiya et al., 2025	Parallel RCT	60	50.9 ± 9.3 vs 55.1 ± 13.6	Moderate–severe (debridement)	NR	Likely infected	CBG ~260 mg/dL
Daphne & Prince, 2019	Quasi-experimental	60	NR	Mild–moderate	NR	NR	NR
Malini et al., 2022	Quasi-experimental	17	53.3 vs 50.6	BWAT stage 2–4	NR	NR	NR
Bahar et al., 2015	Double-blind RCT	39	56.3 ± 10.2	Non-infected, non-ischemic	0.5–4 cm ²	Non-infected	HbA1c measured
Najafian et al., 2019	Double-blind RCT	40	61.5 ± 8.0 vs 57.0 ± 8.4	Wagner 1–2 (neuropathic)	≤2 cm ²	Moderate infection	HbA1c <10%

Notes. DFU = diabetic foot ulcer. Wagner = Wagner ulcer classification system. BWAT/BJWAT = Bates–Jensen Wound Assessment Tool. NR = not reported.

Table 3. Characteristics of Aloe vera Interventions

Study	Aloe Formulation	Intervention Type	Co-interventions	Application Protocol	Frequency	Duration	Comparator
Aqsa et al., 2019	Aloe dressing	Dressing	Standard wound care	Dressing applied topically with routine care	Daily	8 days	Saline dressing
Irani et al., 2024	Aloe gel	Topical gel	Saline wash + sterile dressing	Thin layer applied, followed by dressing and saline wash	Daily	3 weeks	Standard care
Muslim et al., 2025	Aloe gel	Topical gel	Standard wound care	Applied with dressing	Daily	21 days	Saline; Hepar sulph
Sandhiya et al., 2025	100% Aloe vera	Topical gel	Debridement + IV antibiotics + povidone iodine	Applied after debridement	Daily	28 days	Standard care
Daphne & Prince, 2019	Aloe gel	Topical gel	Routine care (unspecified)	Applied topically	Daily	10 days	Routine care
Malini et al., 2022	Aloe gel	Topical gel	Standard nursing care	Applied by nurse	Every 2 days	3 weeks	NaCl 0.9%
Bahar et al., 2015	Aloe (50%) + honey (25%)	Combination gel	Debridement + offloading + saline	Applied with dressing	2× daily	8 weeks	Placebo gel
Najafian et al., 2019	Aloe + Plantago major	Combination gel	Antibiotics + debridement + dressing	5-mm layer applied	2× daily	4 weeks	Placebo gel + standard care

Notes. All groups received background DFU management including debridement, saline irrigation, sterile dressings, infection control, and off-loading as indicated. Plantavera is a herbal gel containing 5% Aloe vera and 5% Plantago major. CMC = Carboxymethyl cellulose

Table 4. Wound-Healing Outcomes and Main Effects of Aloe vera

Study	Primary Outcome	Secondary Outcome	Key Result
Aqsa et al., 2019	–	Granulation tissue formation	100% vs 53.3% (p<0.001); strong early improvement with Aloe across subgroups.
Irani et al., 2024	Wound (BWAT) score	–	Both groups improved (17.1–32.8 vs 18.5–31.4); significant time effect but no overall group difference (p=0.352), suggesting comparable healing.
Muslim et al., 2025	Ulcer reduction size	Time to wound closure	Greater reduction with Aloe (2.5 ± 1.0 vs 1.2 ± 0.8 cm ² , p<0.01); also improved vs saline Faster closure with Aloe (28 ± 3.5 vs 35 ± 4.3 days, p<0.01).
Sandhiya et al., 2025	Wound (BWAT) score	Tissue characteristics (granulation, epithelialization)	Greater reduction in Aloe group (42–19 vs 43–25); ≥22-point improvement in 13 vs 1 patients (p=0.0029).
Daphne & Prince, 2019	Wound (BWAT) score	Adverse events	Significant reduction (35–21 vs control 33); MD=12, p<0.05, favoring Aloe.
Malini et al., 2022	Wound (BJWAT) score	Tissue characteristics (granulation, epithelialization)	Greater improvement in Aloe group (45.6–32.3 vs 42.9–39.7); p=0.001 vs 0.013. Greater improvement in tissue regeneration parameters in Aloe group.
Bahar et al., 2015	Ulcer reduction size	–	Higher healing proportion (95.5% vs 78.6%) but not statistically significant (p=0.11).
Najafian et al., 2019	Ulcer score + surface area	Adverse events	Significant reduction in total score (p<0.001) and surface (p=0.039), but not depth. No adverse effects reported.

Notes. BWAT = Bates–Jensen Wound Assessment Tool. BJWAT = Bates–Jensen Wound Assessment Tool (brief version). Wound area is reported as cm² unless otherwise stated. p-values refer to between-group comparisons.

Table 5. GRADE assessment of the certainty of evidence.

Outcome	Population (I/C)	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Overall Certainty
Wound score (BWAT/BJWAT)	203 / 162	Serious	Serious	Serious	Serious	Undetected	⊗⊗○○ Low
Ulcer size reduction	99 / 79	Some concerns	Serious	Not serious	Serious	Undetected	⊗⊗○○ Low
Granulation healing	/ 100 / 78	Serious	Serious	Serious	Serious	Suspected	⊗○○○ Very Low

Secondary Outcome

For secondary outcomes, findings were more limited but generally supported a beneficial role of Aloe vera. Aqsa et al. (2019) reported markedly higher early granulation tissue formation (100% vs 53.3%; $p<0.001$). Muslim et al. (2025) also observed faster wound closure (28 vs 35 days; $p<0.01$). Improvements in tissue characteristics, including granulation and epithelialization, were noted in studies such as Malini et al. (2022) and Sandhiya et al. (2025) indicating enhanced tissue regeneration. In contrast, combination therapy studies showed less consistent effects, with partial improvements limited to specific domains. Importantly, no adverse effects were reported in studies that assessed safety, suggesting a favorable tolerability profile (Table 4).

Data Synthesis

Overall, Aloe vera-based interventions demonstrated a generally favorable effect on wound healing outcomes, although the magnitude and consistency of these effects varied across clinical contexts and outcome domains. For score-based outcomes (BWAT/BJWAT), most studies reported greater reductions in wound severity in the Aloe groups, accompanied by improvements in tissue characteristics such as granulation and epithelialization. However, this pattern was not universal, as at least one randomized controlled trial showed comparable improvements between intervention and control groups, indicating a substantial contribution from standard wound care.

For size-based outcomes and clinical endpoints, findings also tended to favor Aloe vera, particularly when compared with basic care such as saline dressings, with evidence of greater ulcer size reduction and shorter time to wound closure. Nevertheless, these benefits appeared less consistent in more complex clinical scenarios, including moderate-to-severe ulcers, infected wounds, or settings involving intensive co-interventions such as debridement and antibiotic therapy. This suggests that the observed effects are influenced not only by the intervention itself but also by underlying wound characteristics and concurrent treatments.

When further stratified by intervention type, Aloe-only formulations demonstrated relatively more consistent improvements in early wound healing parameters, including reductions in wound scores and ulcer size, as well as enhanced granulation and epithelialization in several studies. However, these effects were not uniformly observed across all trials, reinforcing the influence of clinical heterogeneity and standard care practices. In contrast, studies evaluating Aloe-containing combination therapies (e.g., Aloe with honey or *Plantago major*) showed more variable results, with some improvements observed but inconsistent statistical significance across outcomes. Importantly, due to the presence of additional bioactive components, these effects cannot be attributed specifically to Aloe vera alone, thereby limiting causal interpretation.

Risk of Bias Assessment

The methodological quality of the included studies showed considerable variation. Among the RCTs, most were judged to have either low risk of bias or some concerns, reflecting generally acceptable study conduct, although several domains such as deviations from intended interventions and outcome measurement were not consistently robust. A smaller proportion of trials were rated as high risk of bias, mainly due to issues related to lack of blinding, incomplete outcome data, or selective reporting.

These limitations may have influenced the reliability of the observed treatment effects (Figure 2).

Certainty of Evidence

The certainty of evidence, assessed using the GRADE approach, was generally low across most outcomes (Table 5). Both wound score-based outcomes and ulcer size reduction were downgraded due to concerns regarding risk of bias, inconsistency, and imprecision, despite a general trend favoring Aloe vera. In contrast, clinical endpoints such as granulation and healing rates were rated as very low certainty, mainly due to heterogeneous outcome definitions and inconsistent results. Overall, these findings suggest that while Aloe vera shows potential benefit, the current evidence remains limited and should be interpreted cautiously.




Figure 2. Traffic light plot of risk of bias using the RoB 2 tool across included studies.

In contrast, the non-randomized studies demonstrated more substantial methodological weaknesses. One study was assessed as having a critical risk of bias, primarily driven by serious confounding and deviations from intended interventions, while the other was judged to have a serious overall risk of bias. These findings indicate that results from non-randomized designs should be interpreted with greater caution, as they are more vulnerable to systematic errors (Figure 3).




Figure 3. Traffic light plot of ROBINS-I tools risk-of-bias across included studies.

DISCUSSION

Overall, the available clinical evidence indicates that topical Aloe vera, when used as an adjunctive therapy, is associated with improvements in several wound healing parameters among patients with DFU, particularly when compared with basic care such as saline dressings or routine wound management. Most included studies, encompassing

both RCTs and quasi-experimental designs, consistently reported improvements in wound assessment scores (BWAT/BJWAT), along with enhanced granulation, epithelialization, and reductions in wound size (Aqsa et al., 2019; Muslim et al., 2025; Daphne & Prince, 2019; Malini et al., 2022; Najafian et al., 2019). Some RCTs further demonstrated greater improvements in wound scores and faster healing progression in the Aloe vera groups compared with controls (Sandhiya et al., 2025), whereas others showed favorable trends without reaching statistical significance (Bahar et al., 2015). However, these findings were not entirely consistent, as highlighted by Irani et al. (2024), where both intervention and control groups improved without significant differences, particularly in superficial and non-ischemic ulcers.

The interpretation of these findings requires caution, as most reported outcomes represent surrogate indicators of wound quality rather than definitive clinical endpoints. The majority of studies had relatively short follow-up durations, typically ranging from 8 to 21 days (Aqsa et al., 2019; Irani et al., 2024; Muslim et al., 2025; Daphne & Prince, 2019; Malini et al., 2022), with only a few extending to 28 days or up to 8 weeks (Bahar et al., 2015; Sandhiya et al., 2025; Najafian et al., 2019). These timeframes predominantly capture the inflammatory and proliferative phases of wound healing rather than the remodeling phase, which requires longer durations for collagen maturation and restoration of tensile strength (El Ayadi et al., 2020). Consequently, the observed benefits likely reflect early healing responses, such as granulation and epithelialization, rather than sustained or complete wound closure (Mo et al., 2022). Although improvements in BWAT/BJWAT scores suggest enhanced wound bed characteristics, their clinical significance remains uncertain due to the absence of established minimal clinically important differences in DFU populations, limiting their direct translation into patient-centered outcomes.

The findings of this review are broadly consistent with previous literature. A systematic review by Hekmatpou et al. (2019) reported beneficial effects of Aloe vera across various wound types, although the overall quality of evidence was limited. Conversely, Dat et al. (2012) concluded that high-quality evidence remains insufficient to support definitive clinical effectiveness. In burn wound populations, meta-analyses by Huang et al. (2024) and Levin et al. (2022) demonstrated accelerated healing with Aloe vera, yet differences in pathophysiology limit direct extrapolation to DFU. Compared with acute burn injuries, DFU is a more complex condition influenced by chronic metabolic and vascular impairments, which likely contributes to the greater heterogeneity and less consistent outcomes observed in this review.

The variability in treatment response observed across studies can be explained by the complex interaction between systemic patient factors, local wound characteristics, and concurrent treatments (Guo & DiPietro, 2010). Poor glycemic control, for instance, is associated with increased oxidative stress, macrophage dysfunction, and prolonged inflammation, all of which impair progression to the proliferative phase (Xiang et al., 2019). Although Aloe vera possesses anti-inflammatory and antioxidant properties that may improve the local wound microenvironment, these effects are unlikely to fully compensate for underlying systemic impairments (Zeng et al., 2020). In addition, deeper or infected ulcers are characterized by increased inflammatory burden, elevated protease activity such as matrix metalloproteinases (MMPs), and impaired tissue perfusion, which may further limit the effectiveness of local therapies (Q. Wang et al., 2025).

This complexity is further compounded by variations in co-interventions across studies, including debridement, infection control, systemic antibiotics, and off-loading strategies. Several trials implemented these standard measures alongside Aloe vera, such as debridement with systemic antibiotics and antiseptic care (Sandhiya et al., 2025), off-loading and wound preparation (Bahar et al., 2015), and antibiotic therapy with routine dressing protocols (Najafian et al., 2019; Irani et al., 2024). These interventions independently influence wound healing outcomes, making it difficult to isolate the specific contribution of Aloe vera (Nahak et al., 2025). Therefore, the observed heterogeneity likely reflects the combined effects of local therapies, systemic conditions, and overall wound care strategies rather than the isolated efficacy of Aloe vera alone (Boulton et al., 2022).

Importantly, additional variability arises from differences in intervention composition across studies. Combination therapies (e.g., Aloe with honey or *Plantago major*) introduce multiple bioactive agents with overlapping antimicrobial, anti-inflammatory, and pro-healing properties, which may act synergistically, redundantly, or even competitively depending on formulation and clinical context (Bahar et al., 2015; Najafian et al., 2019). This complexity increases variability in treatment response and obscures the specific contribution of Aloe vera. In contrast, Aloe-only formulations provide a more direct and biologically coherent intervention, primarily targeting early wound healing processes such as inflammation modulation and fibroblast activation (Aqsa et al., 2019; Irani et al., 2024; Muslim et al., 2025; Daphne & Prince, 2019; Malini et al., 2022; Sandhiya et al., 2025). As a result, although their effects are generally modest, they appear more consistent across studies. These differences highlight that variability in outcomes is not solely due to patient or wound characteristics, but also reflects underlying differences in intervention complexity and mechanistic interactions.

From a biological perspective, the observed clinical effects are supported by mechanisms that directly target key disruptions in DFU wound healing. Normal wound repair involves coordinated phases of hemostasis, inflammation, proliferation, and remodeling (Matei et al., 2025), yet this process is often dysregulated in DFU due to prolonged inflammation and impaired progression to later stages (Bai et al., 2023). Bioactive components of Aloe vera, particularly polysaccharides such as glucomannan and acemannan, have been shown to stimulate fibroblast proliferation, enhance collagen synthesis, and regulate extracellular matrix turnover through modulation of MMP activity (Rahman et al., 2017). Furthermore, upregulation of vascular endothelial growth factor (VEGF) promotes angiogenesis and cellular migration, both of which are essential for tissue repair during the proliferative phase (Irani et al., 2024).

In addition to these structural effects, Aloe vera exerts antioxidant, anti-inflammatory, and antimicrobial activities that contribute to improving the wound microenvironment. Compounds such as flavonoids, vitamins C and E, and phenolic substances help reduce oxidative stress and chronic inflammation, thereby facilitating the transition from the inflammatory to the proliferative phase (Abid et al., 2025; Massoud et al., 2023; Sánchez et al., 2020). Its antimicrobial properties may also reduce microbial burden in mildly contaminated wounds and limit early biofilm formation (Abid et al., 2025; Martin et al., 2025). These mechanisms collectively support the biological plausibility of Aloe vera in enhancing early wound healing processes, although their effectiveness remains contingent on adequate systemic conditions (Hekmatpou et al., 2019).

From a clinical perspective, Aloe vera should be positioned as an adjunctive rather than a primary therapy in DFU management. Nearly all included studies administered Aloe vera alongside standard care, suggesting that its observed benefits are likely additive rather than independent (Hofmann et al., 2023; Seneviratne et al., 2024). Its use appears most appropriate in mild to moderate, non-ischemic DFU, where tissue perfusion is relatively preserved (Shafaie et al., 2020; Wernick et al., 2023). In contrast, in ulcers complicated by severe ischemia or infection, its therapeutic contribution is likely limited due to the dominant influence of systemic and vascular factors (Mohammad Zadeh et al., 2019). Therefore, its role should be interpreted within the context of comprehensive DFU management rather than as a standalone therapeutic intervention.

Nevertheless, the overall certainty of evidence remains low to very low based on GRADE assessment. This is primarily driven by small sample sizes, heterogeneity in study design, and risks of bias related to inadequate randomization and blinding (Hróbjartsson et al., 2014; Gan, 2025). The inclusion of quasi-experimental studies further raises concerns regarding underpowering and the stability of effect estimates (Daphne & Prince, 2019; Malini et al., 2022). Substantial clinical heterogeneity in ulcer severity, infection status, and glycemic control introduces additional confounding. Moreover, most outcomes were based on wound scoring systems such as BWAT/BJWAT, which, although useful for assessing tissue characteristics, remain subjective and may not fully capture clinically meaningful endpoints such as complete wound closure or amputation risk (Bates-Jensen et al., 2019).

Finally, the possibility of publication bias should be considered. Most included studies were small in scale and conducted within limited geographic regions, with a tendency to report positive findings. The absence of formal assessments, such as funnel plot analysis, limits objective evaluation of this bias. In addition, small-study effects may contribute to overestimation of treatment effects. Therefore, the apparent consistency of favorable findings should be interpreted cautiously, considering the potential distortion introduced by publication bias.

CONCLUSIONS AND RECOMMENDATION

Based on the available evidence, topical Aloe vera may be considered as an adjunctive therapy in DFU management, particularly for improving early wound healing parameters such as granulation, epithelialization, and wound scores, with more consistent effects observed in mild to moderate, non-ischemic ulcers. However, the overall certainty of evidence is low, limited by small sample sizes, short follow-up, heterogeneity in study design and clinical characteristics, and reliance on surrogate outcomes, and therefore Aloe vera should not replace standard care. Therefore, further well-designed RCTs with standardized Aloe vera formulations, longer follow-up periods, and the inclusion of clinically meaningful outcomes such as complete wound closure, amputation rates, recurrence, and long-term safety, with systematic reporting of adverse events are required to establish its definitive clinical role.

Acknowledgments

The author gratefully acknowledges the contributions of previous researchers whose work informed this review and

the institutional support that facilitated the completion of this study.

DECLARATION

Ethics approval and consent to participate

Not applicable. This study is a systematic review of published literature and did not involve direct participation of human subjects or animals.

Consent for publication

Not applicable. No individual person's data, images, or identifiable information are included in this article.

Availability of data and materials

All data analyzed in this study are derived from publicly available published articles and are included in this manuscript and its referenced sources.

Conflicts of interest Statement

The author declares no competing interests.

Funding

Not applicable.

Artificial Intelligence-Assisted Technology

Artificial intelligence-assisted tools were used for language refinement and formatting support, but not for data extraction, analysis, interpretation, or scientific decision-making.

Authors' contributions

Syafiq Maulana conceived the study design, developed the methodology, conducted the literature search, performed data curation, formal analysis, investigation, software preparation, visualization, and managed project administration.

ABOUT THE AUTHORS

Syafiq Maulana completed his Bachelor of Medicine (S.Ked) at Universitas Islam Negeri Maulana Malik Ibrahim Malang and is currently undertaking the medical professional program at the same institution. His research interests include molecular medicine, tropical medicine, and clinical biomarkers for the diagnosis of a wide range of diseases.

REFERENCES

- Abid, A., Javed, M., Zafar, S., Hamdani, S. A. Z., Shah, S. H. B. U., Abid, J., & Ahmad, A. M. R. (2025). The green healer: An updated review on the phytochemical profile and therapeutic potential of *Aloe vera*. *Frontiers in Nutrition*, 12, Article 1689700. <https://doi.org/10.3389/fnut.2025.1689700>
- Ahn, S., & He, M. (2026). Forecasting the global burden of peripheral artery disease: Implications for wound healing and healthcare systems. *Burns & Trauma*, 14(1), Article tkag003. <https://doi.org/10.1093/burnst/tkag003>
- Aqsa, T., Shafique, M. S., Qureshi, U., Changeez, M., Farooqi, S. A., & Khan, J. S. (2019). Efficacy of *Aloe vera* cream for healing diabetic foot ulcers. *Journal of Rawalpindi Medical College*, 23(2), 113–115.

- Armstrong, D. G., Tan, T.-W., Boulton, A. J. M., & Bus, S. A. (2023). Diabetic foot ulcers: A review. *JAMA*, 330(1), 62–75. <https://doi.org/10.1001/jama.2023.10578>
- Bahar, A., Saeedi, M., Kashi, Z., Akha, O., Rabiei, K., & Davoodi, M. (2015). The effect of *Aloe vera* and honey gel in healing diabetic foot ulcers. *Journal of Mazandaran University of Medical Sciences*, 25(128), 113–117.
- Bai, Y., Niu, Y., Qin, S., & Ma, G. (2023). A new biomaterial derived from *Aloe vera*-Acemannan from basic studies to clinical application. *Pharmaceutics*, 15(7), Article 1913. <https://doi.org/10.3390/pharmaceutics15071913>
- Bates-Jensen, B. M., McCreath, H. E., Harputlu, D., & Patlan, A. (2019). Reliability of the Bates-Jensen wound assessment tool for pressure injury assessment: The pressure ulcer detection study. *Wound Repair and Regeneration*, 27(4), 386–395. <https://doi.org/10.1111/wrr.12714>
- Boulton, A. J. M., Armstrong, D. G., Löndahl, M., Frykberg, R. G., Game, F. L., Edmonds, M. E., Orgill, D. P., Kramer, K., Gurtner, G. C., Januszky, M., & Vileikyte, L. (2022). New evidence-based therapies for complex diabetic foot wounds. *ADA Clinical Compendia*, 2022(2), 1–23. <https://doi.org/10.2337/db2022-02>
- Chia, A. C. K., Tan, I. E.-H., Tan, Z. N., Yeo, W. J., Zhao, Y., Yap, C. J. Q., Ang, K. A., Au, M. K. H., & Chong, T. T. (2025). Retrospective analysis of value-driven outcomes of diabetic foot ulcer in a tertiary hospital in Singapore. *BMJ Open*, 15(9), Article e099215. <https://doi.org/10.1136/bmjopen-2025-099215>
- Daphne, T. L., & Prince, V. (2019). A study to assess the effectiveness of *Aloe vera* gel dressing on wound status among patients with diabetes mellitus in government hospital, Dindigul. *International Journal of Advances in Nursing Management*, 7(2), 159–162. <https://doi.org/10.5958/2454-2652.2019.00038.6>
- Dat, A. D., Poon, F., Pham, K. B., & Doust, J. (2012). *Aloe vera* for treating acute and chronic wounds. *Cochrane Database of Systematic Reviews*, 2012(2), Article CD008762. <https://doi.org/10.1002/14651858.CD008762.pub2>
- Dawi, J., Tumanyan, K., Tomas, K., Misakyan, Y., Gargaloyan, A., Gonzalez, E., Hammi, M., Tomas, S., & Venketaraman, V. (2025). Diabetic foot ulcers: Pathophysiology, immune dysregulation, and emerging therapeutic strategies. *Biomedicines*, 13(5), Article 1076. <https://doi.org/10.3390/biomedicines13051076>
- Dubský, M., Sojáková, D., Fejfarová, V., & Jude, E. B. (2026). Diabetic peripheral neuropathy: New diagnostics and treatment perspectives. *Drugs & Aging*, 43(1), 29–48. <https://doi.org/10.1007/s40266-025-01267-5>
- El Ayadi, A., Jay, J. W., & Prasai, A. (2020). Current approaches targeting the wound healing phases to attenuate fibrosis and scarring. *International Journal of Molecular Sciences*, 21(3), Article 1105. <https://doi.org/10.3390/ijms21031105>
- Everett, E., & Mathioudakis, N. (2018). Update on management of diabetic foot ulcers. *Annals of the New York Academy of Sciences*, 1411(1), 153–165. <https://doi.org/10.1111/nyas.13569>
- Gan, W. (2025). Impact of sample size and its estimation in medical research. *AJPM Focus*. Advance online publication. <https://doi.org/10.1016/j.focus.2025.100451>
- Guo, S., & DiPietro, L. A. (2010). Factors affecting wound healing. *Journal of Dental Research*, 89(3), 219–229. <https://doi.org/10.1177/0022034509359125>
- Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 336(7650), 924–926. <https://doi.org/10.1136/bmj.39489.470347.AD>
- Hassan, N., Ilyas, A., Memon, M. F., Shafiq, Y., Zahra, S. I., Arif, A., & Nawab, S. N. (2026). Gene expression analysis of diabetic foot ulcers reveals the potential impact of levofloxacin on wound healing. *Scientific Reports*, 16(1), Article 3832. <https://doi.org/10.1038/s41598-025-33932-5>
- Hekmatpou, D., Mehrabi, F., Rahzani, K., & Aminiyan, A. (2019). The effect of *Aloe vera* clinical trials on prevention and healing of skin wound: A systematic review. *Iranian Journal of Medical Sciences*, 44(1), 1–9. <https://doi.org/10.30476/ijms.2019.40612>
- Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (Eds.). (2024). *Cochrane handbook for systematic reviews of interventions* (Version 6.5). Cochrane.
- Hofmann, A. T., Slezak, P., Neumann, S., Ferguson, J., Redl, H., & Mittermayr, R. (2023). Ischemia impaired wound healing model in the rat—Demonstrating its ability to test proangiogenic factors. *Biomedicines*, 11(4), Article 1043. <https://doi.org/10.3390/biomedicines11041043>
- Hróbjartsson, A., Emanuelsson, F., Thomsen, A. S. S., Hilden, J., & Brorson, S. (2014). Bias due to lack of patient blinding in clinical trials: A systematic review of trials randomizing patients to blind and nonblind sub-studies. *International Journal of Epidemiology*, 43(4), 1272–1283. <https://doi.org/10.1093/ije/dyu115>
- Huang, Y. N., Chen, K. C., Wang, J. H., & Lin, Y. K. (2024). Effects of *Aloe vera* on burn injuries: A systematic review and meta-analysis of randomized controlled trials. *Journal of Burn Care & Research*, 45(6), 1536–1545. <https://doi.org/10.1093/jbcr/irae061>
- Idrus, A. N., Rehman, K., & Zulfakar, M. H. (2023). A systematic review of the clinical effectiveness of *Aloe vera* for the prevention and treatment of chronic wounds. *Sains Malaysiana*, 52(6), 1785–1794. <https://doi.org/10.17576/jsm-2023-5206-14>
- Irani, P. S., Ranjbar, H., Mehdipour-Rabori, R., Torkaman, M., Amirsalari, S., & Alazmani-Nooddeh, F. (2024). The effect of *Aloe vera* on the healing of diabetic foot ulcer: A randomized, double-blind clinical trial. *Current Drug Discovery Technologies*, 21(3), 56–63. <https://doi.org/10.2174/1570163820666230904150945>
- Jamiyanti, A., Pahria, T., & Nursiswati, N. (2023). Topical effects of *Aloe vera* in healing diabetic foot ulcers: A protocol of systematic review. *Malaysian Journal of Medicine and Health Sciences*, 19(6), 355–359. <https://doi.org/10.47836/mjmhs.19.6.46>
- Levin, N. J., Erben, Y., Li, Y., Brigham, T. J., & Bruce, A. J. (2022). A systematic review and meta-analysis comparing burn healing outcomes between silver sulfadiazine and *Aloe vera*. *Cureus*, 14(10), Article e30815. <https://doi.org/10.7759/cureus.30815>
- Li, T., Higgins, J. P. T., & Deeks, J. J. (2024). Chapter 5: Collecting data. In J. P. T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, & V. A. Welch (Eds.), *Cochrane handbook for systematic reviews of interventions* (Version 6.5). Cochrane.
- Malini, H., Sari, Y. K., & Oktarina, E. (2022). Effect of *Aloe vera* gel on wound healing process for diabetic foot ulcers: A

- pilot study. *Gaceta Médica de Caracas*, 130(Suppl. 5), S967–S973. <https://doi.org/10.47307/GMC.2022.130.s5.15>
- Martin, S. S., Zhang, L., Wang, Y., Zhou, Z., Ma, R., Mo, H., Tan, Z., Shi, H., & Wang, T. (2025). Advances in preparation techniques and antimicrobial properties of *Aloe vera* extract. *Fitoterapia*, 185, Article 106696. <https://doi.org/10.1016/j.fitote.2025.106696>
- Massoud, D., Alrashdi, B. M., Fouda, M. M. A., El-Kott, A., Soliman, S. A., & Abd-Elhafeez, H. H. (2023). *Aloe vera* and wound healing: A brief review. *Brazilian Journal of Pharmaceutical Sciences*, 58, Article e20837. <https://doi.org/10.1590/s2175-97902022e20837>
- Matei, C. E., Visan, A. I., & Cristescu, R. (2025). *Aloe vera* polysaccharides as therapeutic agents: Benefits versus side effects in biomedical applications. *Polysaccharides*, 8(2), Article 36. <https://doi.org/10.3390/polysaccharides6020036>
- McDermott, K., Fang, M., Boulton, A. J. M., Selvin, E., & Hicks, C. W. (2023). Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. *Diabetes Care*, 46(1), 209–221. <https://doi.org/10.2337/dci22-0043>
- Mo, F., Zhang, M., Duan, X., Lin, C., & You, T. (2022). Recent advances in nanozymes for bacteria-infected wound therapy. *International Journal of Nanomedicine*, 17, 5947–5990. <https://doi.org/10.2147/IJN.S382796>
- Mohammad Zadeh, M., Lingsma, H., van Neck, J. W., Vasilic, D., & van Dishoeck, A. (2019). Outcome predictors for wound healing in patients with a diabetic foot ulcer. *International Wound Journal*, 16(6), 1339–1346. <https://doi.org/10.1111/iwj.13194>
- Muslim, D. N. A. M., Said, F. M., Nambiar, N., Khotimah, N. I. H., & Sarinengsih, Y. (2025). Comparison of wound healing process between Hepar sulph with *Aloe vera* wound care dressing treatment among diabetic foot ulcers: A pilot study. *Holistic Nursing Plus*, 3(1), 39–45. <https://doi.org/10.58439/hnp.v3i1.307>
- Najafian, Y., Khorasani, Z. M., Najafi, M. N., Hamed, S. S., Mahjour, M., & Feyzabadi, Z. (2019). Efficacy of *Aloe vera*/*Plantago major* gel in diabetic foot ulcer: A randomized double-blind clinical trial. *Current Drug Discovery Technologies*, 16(2), 223–231. <https://doi.org/10.2174/1570163815666180115093007>
- Nahak, B. K., Chowdhury, J. R., Sharma, M. K., Khan, A., Ganguly, A., Singh, U. K., Parashar, P., Kuan, C.-H., Cheng, N.-C., & Lin, Z.-H. (2025). Advancements in multimodal approaches for enhanced wound healing: From chemical to physical strategies. *Materials Today*, 88, 1087–1125. <https://doi.org/10.1016/j.mattod.2025.07.009>
- Narzary, I., Swarnakar, A., Kalita, M., Middha, S. K., Usha, T., Babu, D., Mochahary, B., Brahma, S., Basumaty, J., & Goyal, A. K. (2023). Acknowledging the use of botanicals to treat diabetic foot ulcer during the 21st century: A systematic review. *World Journal of Clinical Cases*, 11(17), 4035–4059. <https://doi.org/10.12998/wjcc.v11.i17.4035>
- Ndosi, M., Wright-Hughes, A., Brown, S., Backhouse, M., Lipsky, B. A., Bhogal, M., Reynolds, C., Vowden, P., Jude, E. B., Nixon, J., & Nelson, E. A. (2018). Prognosis of the infected diabetic foot ulcer: A 12-month prospective observational study. *Diabetic Medicine*, 35(1), 78–88. <https://doi.org/10.1111/dme.13537>
- Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan—A web and mobile app for systematic reviews. *Systematic Reviews*, 5, 210. <https://doi.org/10.1186/s13643-016-0384-4>
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>
- Parveen, K., Hussain, M. A., Anwar, S., Elagib, H. M., & Kausar, M. A. (2025). Comprehensive review on diabetic foot ulcers and neuropathy: Treatment, prevention and management. *World Journal of Diabetes*, 16(3), Article 100329. <https://doi.org/10.4239/wjd.v16.i3.100329>
- Pinem, V. A. B., Perdanakusuma, D. S., Ervianti, E., Teferi, M. G., & Al-Taie, H. A. (2025). Chronic wounds: Risk factors and evidence-based intervention. *Jurnal Rekonstruksi dan Estetik*, 10(1), 56–66. <https://doi.org/10.20473/jre.v10i1.66610>
- Rahman, S., Carter, P., & Bhattarai, N. (2017). *Aloe vera* for tissue engineering applications. *Journal of Functional Biomaterials*, 8(1), Article 6. <https://doi.org/10.3390/jfb8010006>
- Rethlefsen, M. L., Kirtley, S., Waffenschmidt, S., Ayala, A. P., Moher, D., Page, M. J., Koffel, J. B., & PRISMA-S Group. (2021). PRISMA-S: An extension to the PRISMA Statement for reporting literature searches in systematic reviews. *Systematic Reviews*, 10, 39. <https://doi.org/10.1186/s13643-020-01542-z>
- Sánchez, M., González-Burgos, E., Iglesias, I., & Gómez-Serranillos, M. P. (2020). Pharmacological update properties of *Aloe vera* and its major active constituents. *Molecules*, 25(6), Article 1324. <https://doi.org/10.3390/molecules25061324>
- Seneviratne, D. M., Raphael, B., Whiteside, E. J., Windus, L. C. E., Kauter, K., Dearnaley, J. D. W., Annamalai, P. K., Ward, R., Song, P., & Burey, P. (2024). A low-cost, antimicrobial aloe-alginate hydrogel film containing Australian First Nations remedy 'lemon myrtle oil' (*Backhousia citriodora*)—Potential for incorporation into wound dressings. *Heliyon*, 10(18), Article e37516. <https://doi.org/10.1016/j.heliyon.2024.e37516>
- Shafaie, S., Andalib, S., Shafaei, H., Montaseri, A., & Tavakolizadeh, M. (2020). Differential biological behavior of fibroblasts and endothelial cells under *Aloe vera* gel culturing. *International Journal of Molecular and Cellular Medicine*, 9(3), 234–246. <https://doi.org/10.22088/IJMCM.BUMS.9.3.234>
- Shahzad, M. N., & Ahmed, N. (2013). Effectiveness of *Aloe vera* gel compared with 1% silver sulphadiazine cream as burn wound dressing in second degree burns. *Journal of the Pakistan Medical Association*, 63(2), 225–230.
- Sandhiya, T., Adalarasan, S., U, S., Md, S., & R, R. (2025). A randomized controlled trial on the therapeutic effect of *Aloe vera* extract on diabetic foot ulcers. *Cureus*, 17(7), Article e88956. <https://doi.org/10.7759/cureus.88956>
- Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., Emberson, J. R., Hernán, M. A., Hopewell, S., Hróbjartsson, A., Junqueira, D. R., Jüni, P., Kirkham, J. J., Lasserson, T., Li, T., ... Higgins, J. P. T. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ*, 366, 14898. <https://doi.org/10.1136/bmj.14898>

- Sterne, J. A. C., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., Carpenter, J. R., Chan, A.-W., Churchill, R., Deeks, J. J., Hróbjartsson, A., Kirkham, J., Jüni, P., Loke, Y. K., Pigott, T. D., ... Higgins, J. P. T. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*, 355, i4919. <https://doi.org/10.1136/bmj.i4919>
- Wang, Q., Liu, C., An, J., Liu, J., Wang, Y., & Cai, Y. (2025). Mechanisms of microbial infection and wound healing in diabetic foot ulcer: Pathogenicity in the inflammatory-proliferative phase, chronicity, and treatment strategies. *Frontiers in Endocrinology*, 16, Article 1657928. <https://doi.org/10.3389/fendo.2025.1657928>
- Wang, R., Gu, S., Kim, Y. H., Lee, A., Lin, H., & Jiang, D. (2025). Diabetic wound repair: From mechanism to therapeutic opportunities. *MedComm*, 6(10), Article e70406. <https://doi.org/10.1002/mco2.70406>
- Wang, X., Yuan, C. X., Xu, B., & Yu, Z. (2022). Diabetic foot ulcers: Classification, risk factors and management. *World Journal of Diabetes*, 13(12), 1049–1065. <https://doi.org/10.4239/wjd.v13.i12.1049>
- Wernick, B., Nahirniak, P., & Stawicki, S. P. (2023). Impaired wound healing. In *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK482254/>
- Xiang, J., Wang, S., He, Y., Xu, L., Zhang, S., & Tang, Z. (2019). Reasonable glycemic control would help wound healing during the treatment of diabetic foot ulcers. *Diabetes Therapy*, 10(1), 95–105. <https://doi.org/10.1007/s13300-018-0536-8>
- Zeng, W., Parus, A., Barnes, C., Hiro, M., Robson, M., & Payne, W. (2020). *Aloe vera*—Mechanisms of action, uses, and potential uses in plastic surgery and wound healing. *Surgical Science*, 11, 312–328. <https://doi.org/10.4236/ss.2020.1110033>

ADDITIONAL INFORMATION

Correspondence All inquiries and requests for additional materials should be directed to the Corresponding Author.

Publisher's Note Utan Kayu Publishing maintains a neutral stance regarding territorial claims depicted in published maps and does not endorse or reject the institutional affiliations stated by the authors.

Open Access This article is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), which permits others to share, adapt, and redistribute the material in any medium or format, even for commercial purposes, provided appropriate credit is given to the original author(s) and the source, a link to the license is provided, and any changes made are indicated. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. To view a copy of this license, visit <https://creativecommons.org/licenses/by-sa/4.0/>.

© The Author(s) 2026

This page has been intentionally left blank